After vaccine advisers to the US Food and Drug Administration rejected Pfizer's application to add a booster dose of its Covid-19 vaccine, several members of the committee voiced doubts that it is a good idea to start giving boosters to the entire population.
They especially expressed concern about younger adults and older teens, who may have a higher risk of a rare complication called myocarditis – an inflammation of the heart.
“I have major concerns with regard to the extrapolation of data from much older populations to 16- and 17- year-olds,” said Dr. Archana Chatterjee, dean of the Chicago Medical School at Rosalind Franklin University. “We have no data on the safety in this population at all, that have been presented so far, and, and that concerns me significantly,” she added.
“Recommending a third dose for younger people is not something I would be comfortable with at this point,” said Dr. Melinda Wharton, director of immunization services at the US Centers for Disease Control and Prevention.
The committee is now discussing voting on another question limiting the approval of a booster dose to a more limited group.